Li Chen-Xi, Wang Zheng-Ye, Tong Qiao-Ying, Li Mu-Qiu, Wei Wei, Gong Zhong-Cheng
Department of Oral and Maxillofacial Oncology & Surgery, School / Hospital of Stomatology, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Stomatological Research Institute of Xinjiang Uygur Autonomous Region, Urumqi, China.
Ear Nose Throat J. 2023 Nov 23:1455613231210388. doi: 10.1177/01455613231210388.
The treatment of oral squamous cell carcinoma (OSCC) is dominated by surgery and radiochemotherapy, but its prognosis is still unsatisfactory, with around five tenths of 5-year survival. This study aimed to assess the prognosis of OSCC patients treated with surgery with and without postoperative radiotherapy. Retrospective study. The clinicopathological information and follow-up datasets on patients with OSCC (T and/or N+) registered from 2010 to 2015 were downloaded from the Surveillance, Epidemiology, and End Results database. Totally 7231 enrolled subjects were divided into a case group (surgery alone, n = 4167) and a control group (surgery combined with postoperative radiotherapy, n = 3064). One-to-one matching was performed by propensity score matching to make the baseline data comparable between the 2 subgroups. Multivariate regression analysis was used to calculate hazard ratios (HR) of various clinicopathological features. The method and test were used to plot the survival curves. The majority of patients in case group were tumor stage I (n = 2569, 61.7%), whereas most patients in control group were stages III to IV (n = 2360, 77.1%). In the case group, the 1-, 3-, and 5-year overall survival (OS; 76%, 59.5%, 53.7%) were significantly lower than those of the control group (85.1%, 64.1%, 55.8%; < .0001). Similarly, the 1-, 3-, and 5-year cancer-specific survival (CSS) of the case group (80.2%, 66.6%, 63.3%) were significantly lower than those of the control group (87.2%, 69.3%, 63.9%, respectively; < .0001). multivariate analysis indicated that age, differentiation, clinical stage, and tumor-node-metastasis stage affected the prognosis of OSCC patients, while postoperative radiotherapy was a protective factor (OS: HR = 0.649, < .001; CSS: HR = 0.702, < .001). Postoperative radiation was an independent protective factor, hence, the combination of surgery plus radiotherapy is more beneficial for the survival of patients with OSCC, particularly for advanced cases.
口腔鳞状细胞癌（OSCC）的治疗以手术和放化疗为主，但其预后仍不尽人意，5年生存率约为十分之五。本研究旨在评估接受手术治疗且有或无术后放疗的OSCC患者的预后。回顾性研究。从监测、流行病学和最终结果数据库下载了2010年至2015年登记的OSCC患者（T和/或N+）的临床病理信息和随访数据集。总共7231名纳入受试者被分为病例组（单纯手术，n = 4167）和对照组（手术联合术后放疗，n = 3064）。通过倾向得分匹配进行一对一匹配，以使两个亚组之间的基线数据具有可比性。采用多因素回归分析计算各种临床病理特征的风险比（HR）。采用该方法和检验绘制生存曲线。病例组中的大多数患者为肿瘤I期（n = 2569，61.7%），而对照组中的大多数患者为III至IV期（n = 2360，77.1%）。病例组的1年、3年和5年总生存率（OS；76%、59.5%、53.7%）显著低于对照组（85.1%、64.1%、55.8%；P <.0001）。同样，病例组的1年、3年和5年癌症特异性生存率（CSS）（80.2%、66.6%、63.3%）显著低于对照组（分别为87.2%、69.3%、63.9%；P <.0001）。多因素分析表明，年龄、分化程度、临床分期和肿瘤-淋巴结-转移分期影响OSCC患者的预后，而术后放疗是一个保护因素（OS：HR = 0.649，P <.001；CSS：HR = 0.702，P <.001）。术后放疗是一个独立的保护因素，因此，手术加放疗的联合治疗对OSCC患者的生存更有益，尤其是对于晚期病例。
